Person: ALİYEV, ALTAY
Now showing 1 - 3 of 3
- PublicationOpen AccessEvaluation of Kidney Function in Patients on Chemotherapy(2021-04-01T00:00:00Z) Haziyev, Elgun; GÜRSU, Meltem; ŞEKER, Mesut; ELÇİOĞLU, Ömer Celal; ARTAN, AYŞE SERRA; ALİYEV, Altay; TÜRK, HACI MEHMET; DEMİR, Tarık; TOPRAK, ALİ; KAZANCIOĞLU, Rümeyza; GÜRSU, MELTEM; ŞEKER, MESUT; ELÇİOĞLU, ÖMER CELAL; ARTAN, AYŞE SERRA; ALİYEV, ALTAY; TÜRK, HACI MEHMET; DEMİR, TARıK; TOPRAK, ALİ; KAZANCIOĞLU, RÜMEYZAObjective: We aimed to study whether long-term kidney function would be affected by different chemotherapy regimens in patients with malignancy.
- PublicationOpen AccessPrimitive Neuroectodermal Tumor of the Testis(2021-11-01T00:00:00Z) DEMİR, Tarık; ALİYEV, Altay; ŞEKER, Mesut; ERSÖZ, CEVPER; ÇOBAN, GANİME; TÜRK, HACI MEHMET; DEMİR, TARıK; ALİYEV, ALTAY; ŞEKER, MESUT; ERSÖZ, CEVPER; ÇOBAN, GANİME; TÜRK, HACI MEHMETA 21-year male presenting with left testicular mass and retroperitoneal lymphadenopathy underwent radical orchiectomy; and his pathological examination showed a mixed germ cell tumor composed of primitive neuroectodermal tumor mixed with mature teratoma. Six cycles of IE (ifosfamide, etoposide) and VAC (vincristine, doxorubicin, cyclophosphamide) chemotherapy were given after sperm preservation. He then underwent retroperitoneal lymph node dissection (RPLND). No tumor was detected in the removed lymph nodes, and all lymph nodes were reported as showing reactive changes.
- PublicationMetadata onlyRole of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients(2018-01-01) Seker, MESUT; ISEN, Hayati C.; Cevirme, NİDAL; Aydin, Sinem; Bilici, Ahmet; COBAN, EZGİ; YASIN, Ayse I.; Demir, TARIK; Aliyev, ALTAY; Kocyigit, ABDÜRRAHİM; Turk, Haci M.; ŞEKER, MESUT; ÇEVİRME, NİDAL; BULUT, HURI; ÇOBAN, EZGİ; DEMİR, TARıK; ALİYEV, ALTAY; KOÇYİĞİT, ABDÜRRAHİM; TÜRK, HACI MEHMETBackground: The aim of this study was to identify the possible relationship of 5-fluorouracil (5-FU)-related arterial vasoconstriction with urotensin-2 (UT-2), which has a high potential as an endogenic vasoconstrictor. Methods: We assigned the patients to 1 of 3 groups. Patients in group 1 received a bolus of 5-FU, those in group 2 a continuous infusion (CI) of 5-FU, and those in group 3 no 5-FU, which was also a control group. Pre- and post-treatment UT-2 levels and brachial arterial diameters were measured and recorded in all patients. Results: 132 patients were included in the study. Pre-and post-treatment brachial artery diameters were similar in all groups: in group 1 (3.28 +/- 0.52 vs. 3.25 +/- 0.44 mm, p = 0.740), in group 2 (3.57 +/- 0.47 vs. 3.46 +/- 0.45 mm, p = 0.441) and in the control group (3.51 +/- 0.52 vs. 3.25 +/- 0.44 mm, p = 0.818). Pre-and post-treatment UT-2 levels were significantly different in each group: in group 1 (39.5 +/- 30.9 vs. 56.7 +/- 27.1 ng/ml, p = 0.0001), in group 2 (37.7 +/- 33.7 vs. 62.5 +/- 37.7 ng/ml, p = 0.0001) and in the control group (52.9 +/- 40.2 vs. 60.8 +/- 40.7 ng/ml, p = 0.006). Conclusion: Our findings suggest that UT-2 has a high potential as a vasoconstrictor agent in our bodies and its level increases through a bolus or CI 5-FU. Increased UT-2 levels are likely to play a role in 5-FU-related cardiac toxicity pathogenesis. (c) 2018 S. Karger GmbH, Freiburg